CN109414483B - 对补体灭活作用具有抗性的用于治疗癌症的包膜病毒 - Google Patents

对补体灭活作用具有抗性的用于治疗癌症的包膜病毒

Info

Publication number
CN109414483B
CN109414483B CN201880002553.7A CN201880002553A CN109414483B CN 109414483 B CN109414483 B CN 109414483B CN 201880002553 A CN201880002553 A CN 201880002553A CN 109414483 B CN109414483 B CN 109414483B
Authority
CN
China
Prior art keywords
virus
sequence
fusion protein
cell line
thr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880002553.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN109414483A (zh
Inventor
罗天赐
R·莫丽娜
G·卡斯蒂尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmaceutical Co ltd
Original Assignee
Pharmaceutical Co ltd
Wellstat ImmunoTherapeutics LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmaceutical Co ltd, Wellstat ImmunoTherapeutics LLC filed Critical Pharmaceutical Co ltd
Publication of CN109414483A publication Critical patent/CN109414483A/zh
Application granted granted Critical
Publication of CN109414483B publication Critical patent/CN109414483B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/036—Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18151—Methods of production or purification of viral material
    • C12N2760/18152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201880002553.7A 2017-05-10 2018-05-10 对补体灭活作用具有抗性的用于治疗癌症的包膜病毒 Active CN109414483B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762504120P 2017-05-10 2017-05-10
US62/504,120 2017-05-10
PCT/US2018/032018 WO2018209052A1 (en) 2017-05-10 2018-05-10 Enveloped virus resistant to complement inactivation for the treatment of cancer

Publications (2)

Publication Number Publication Date
CN109414483A CN109414483A (zh) 2019-03-01
CN109414483B true CN109414483B (zh) 2025-10-24

Family

ID=64105722

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880002553.7A Active CN109414483B (zh) 2017-05-10 2018-05-10 对补体灭活作用具有抗性的用于治疗癌症的包膜病毒

Country Status (12)

Country Link
US (2) US11274141B2 (enExample)
EP (1) EP3621635A4 (enExample)
JP (1) JP7161940B2 (enExample)
KR (3) KR20250118857A (enExample)
CN (1) CN109414483B (enExample)
AU (1) AU2018265258B2 (enExample)
BR (1) BR112018075281A2 (enExample)
CA (1) CA3026892A1 (enExample)
IL (1) IL263979B2 (enExample)
MX (1) MX2018015599A (enExample)
WO (1) WO2018209052A1 (enExample)
ZA (1) ZA201808040B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3056630A1 (en) 2017-03-15 2018-09-20 Pandion Therapeutics, Inc. Targeted immunotolerance
JP2020521452A (ja) 2017-05-24 2020-07-27 パンディオン・セラピューティクス・インコーポレイテッド 標的化免疫寛容
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
US10174091B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
USRE50550E1 (en) 2017-12-06 2025-08-26 Pandion Operations, Inc. IL-2 muteins and uses thereof
CN112759654A (zh) * 2019-11-06 2021-05-07 深圳普菲科生命科技有限公司 一种病毒囊膜蛋白装配系统及其方法和应用
WO2021168079A1 (en) 2020-02-21 2021-08-26 Pandion Operations, Inc. Tissue targeted immunotolerance with a cd39 effector
US20240067936A1 (en) * 2021-02-26 2024-02-29 Sillajen, Inc. Oncolytic virus and uses thereof
CN113736810B (zh) * 2021-09-08 2024-05-24 苏州因特药物研发有限公司 构建体、载体、蛋白、细胞、制备方法、产品及应用
KR20240003051A (ko) * 2022-06-29 2024-01-08 신라젠(주) Cd55 및 cd59를 동시 발현하는 항암 바이러스
JP2025531806A (ja) * 2022-09-07 2025-09-25 シルラジェン，インコーポレイテッド 抗癌ウイルスの新規用途

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5374548A (en) * 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
ATE411809T1 (de) 1993-04-30 2008-11-15 Wellstat Biologics Corp Zusuammensetzungen zur behandlung von krebs mittels viren
JPH10313865A (ja) * 1997-05-15 1998-12-02 Deinabetsuku Kenkyusho:Kk ヒト補体制御因子が呈示されたベクター
WO1999027121A1 (en) 1997-11-21 1999-06-03 GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) Development of viruses resistant to inactivation by the human complement system
WO1999032648A1 (en) 1997-12-22 1999-07-01 The University Of Tennessee Research Corporation Recombinant rhabdovirus containing a heterologous fusion protein
EP1071705A2 (en) * 1998-04-02 2001-01-31 Rigel Pharmaceuticals, Inc. Peptides causing formation of compact structures
CN1477964A (zh) 1999-04-15 2004-02-25 应用病毒治疗肿瘤
DK1569685T3 (da) * 2002-11-15 2012-11-12 Univ Colorado Regents Komplementmodulatorer rettet mod komplementreceptor-2
US8828727B2 (en) * 2004-07-21 2014-09-09 Dana-Farber Cancer Institute Lentiviral vectors and uses thereof
JP5050198B2 (ja) * 2006-09-05 2012-10-17 国立大学法人大阪大学 ヒト補体制御因子発現遺伝子およびその利用
CA2676090A1 (en) * 2007-02-06 2008-10-02 Genizon Biosciences Inc. Genemap of the human genes associated with adhd
CA2678774A1 (en) * 2007-03-01 2008-09-04 Advanced Vision Therapies, Inc. Treatment of diseases characterized by inflammation
US8877896B2 (en) 2008-02-15 2014-11-04 Tufts University Compositions, methods and kits for modeling, diagnosing, and treating complement disorders
US20140206850A1 (en) 2011-04-29 2014-07-24 Keygene N.V. Glyphosate resistance enhancement
KR101949293B1 (ko) 2011-05-05 2019-02-18 웰스태트 이뮤노테라퓨틱스, 엘엘씨 보체 인자 ｂ 유사체 및 그의 용도
AU2012318288B2 (en) * 2011-12-01 2015-09-17 Ap Biosciences, Inc. Protein inhibitors to complement and VEGF pathways and methods of use thereof
PL3888674T3 (pl) * 2014-04-07 2024-09-23 Novartis Ag Leczenie nowotworu złośliwego z zastosowaniem chimerycznego receptora antygenowego anty-CD19
EP3805371A1 (en) 2014-05-15 2021-04-14 National University of Singapore Modified natural killer cells and uses thereof
MX387517B (es) 2015-04-06 2025-03-18 Subdomain Llc Polipeptidos que contienen dominios de union de novo y usos de los mismos.
GB201507119D0 (en) * 2015-04-27 2015-06-10 Ucl Business Plc Nucleic Acid Construct
EP3307282A4 (en) 2015-06-12 2019-05-01 Immunomedics, Inc. DISEASE THERAPY WITH CONSTRUCTS OF CHIMERIC ANTIGEN RECEPTOR (CAR) AND T-CELL (CAR-T) OR NK-CELL (CAR-NK) EXPRESSIVE CAR CONSTRUCTS
US20190282640A1 (en) 2016-05-19 2019-09-19 Turnstone Limited Partnership Pseudotyped oncolytic rhabdoviruses and their use in combination therapy

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
嵌合跨膜型人 CD55基因的重组逆病毒表达质粒的构建;杜瑞琴等;第三军医大学学报;第23卷(第23期);第48-51页，尤其是第48页摘要，第49页第2.1-2.2节，第50页右栏第1段 *

Also Published As

Publication number Publication date
KR102662049B1 (ko) 2024-05-23
KR20200005721A (ko) 2020-01-16
EP3621635A4 (en) 2021-02-24
BR112018075281A2 (pt) 2020-02-11
AU2018265258B2 (en) 2023-01-05
IL263979A (en) 2019-02-28
RU2018146446A (ru) 2021-06-10
US11274141B2 (en) 2022-03-15
IL263979B2 (en) 2023-09-01
KR20250118857A (ko) 2025-08-06
IL263979B1 (en) 2023-05-01
MX2018015599A (es) 2019-05-16
US20190194292A1 (en) 2019-06-27
CA3026892A1 (en) 2018-11-15
KR20240073085A (ko) 2024-05-24
JP7161940B2 (ja) 2022-10-27
CN109414483A (zh) 2019-03-01
EP3621635A1 (en) 2020-03-18
ZA201808040B (en) 2019-09-25
JP2020519230A (ja) 2020-07-02
WO2018209052A1 (en) 2018-11-15
US20220169701A1 (en) 2022-06-02
AU2018265258A1 (en) 2019-01-17
KR102839445B1 (ko) 2025-07-28
RU2018146446A3 (enExample) 2021-09-10

Similar Documents

Publication Publication Date Title
CN109414483B (zh) 对补体灭活作用具有抗性的用于治疗癌症的包膜病毒
CN112680466B (zh) 一种表达人源ace2的动物模型及其用途
CN112522271B (zh) 一种sgRNA及其应用
KR20220066914A (ko) 부정맥 유발성 우심실 심근병증의 유전자 요법 조성물 및 치료
CN110650975A (zh) 双顺反子嵌合抗原受体及其用途
KR102673828B1 (ko) off-the-shelf 줄기세포 및 면역세포, 이를 포함하는 약학적 조성물
KR101229418B1 (ko) 활성형 재조합 혈액응고 9인자의 대량생산 방법
CN117715660A (zh) 右心室致心律失常性心肌病的基因治疗组合物和治疗
CN117136232A (zh) 嵌合抗原受体（car）nk细胞及其用途
CN111269888B (zh) 一种adipsin基因修饰的脂肪干细胞、制备方法及其应用
CN108379597B (zh) 一种基因载体及其用于治疗视网膜神经节细胞变性的基因治疗药物
KR101885438B1 (ko) 유전자치료 벡터시스템 및 전구약물 유전자
CN114107390B (zh) 一种用于表达抗体IgG1的rAAV载体及其应用
CN112342228B (zh) 表达抗vegf融合蛋白的aav病毒载体及其应用
CN111793632A (zh) 变异的Gsdmd-C核酸片段，包含所述核酸片段的载体及应用
CN112301058B (zh) 一种重组腺相关病毒载体及其制备方法与应用
RU2791051C2 (ru) Оболочечный вирус, резистентный к инактивации комплементом, для лечения злокачественных новообразований
CN110225977B (zh) 基因治疗载体系统和药物前体基因
CN109735558B (zh) 一种重组car19-il24基因、慢病毒载体、car19-il24-t细胞及应用
CN112301057B (zh) 一种重组腺相关病毒载体及其制备方法与应用
US20020103144A1 (en) Retroviral gene transfer vectors
CN109022487A (zh) 一种表达p65的基因载体及其用于治疗视网膜神经节细胞变性的基因治疗药物
CN114686521A (zh) 一种重组腺相关病毒载体及其制备方法与应用
CN111088204A (zh) 表达Caspase-3重组scFv78的重组大肠杆菌及其功能验证方法
RU2805173C1 (ru) Способ получения генно-модифицированных лабораторных животных с нуль-аллелем гена P2rx3

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20240619

Address after: American Maryland

Applicant after: Pharmaceutical Co.,Ltd.

Country or region after: U.S.A.

Address before: American Maryland

Applicant before: WELLSTAT IMMUNOTHERAPEUTICS, LLC

Country or region before: U.S.A.

GR01 Patent grant
GR01 Patent grant